Jul 14, 2026 11:39AM
Jul 13, 2026 10:38PM
Jul 13, 2026 10:37PM
Jul 13, 2026 12:02AM
Jun 30, 2026 02:44AM
Jun 16, 2026 08:00AM
Jun 16, 2026 08:00AM BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
May 25, 2026 03:33AM
May 15, 2026 02:55AM
May 8, 2026 09:00AM
May 8, 2026 02:48AM
May 8, 2026 02:48AM
May 8, 2026 02:47AM
Apr 21, 2026 07:01AM BioAge reports phase 1 results for NLRP3 inhibitor BGE-102
Apr 21, 2026 07:00AM
Mar 24, 2026 09:00AM
Mar 23, 2026 03:50AM
Feb 6, 2026 06:17AM
Jan 21, 2026 10:30PM
Jan 21, 2026 10:30PM
Jan 20, 2026 04:01PM BioAge plans $75 million public stock offering to fund drug development
Jan 20, 2026 04:01PM
Jan 20, 2026 09:01AM
Jan 20, 2026 09:00AM
Jan 12, 2026 09:01AM
Jan 12, 2026 09:00AM
Dec 8, 2025 06:42PM
Dec 4, 2025 09:01AM BioAge reports positive phase 1 data for brain-penetrant drug BGE-102
Dec 4, 2025 09:00AM
Dec 4, 2025 02:13AM
Nov 18, 2025 07:02PM
Nov 13, 2025 06:50PM
Nov 6, 2025 04:45PM
Oct 26, 2025 10:56PM
Sep 2, 2025 11:01PM Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status
Aug 25, 2025 03:26AM
Aug 15, 2025 09:00AM
Aug 15, 2025 09:00AM
Aug 6, 2025 04:30PM
Jul 30, 2025 10:54PM
Jun 21, 2025 06:00PM
Jun 17, 2025 09:08AM BioAge Labs (BIOA) expands drug discovery platform with samples from Norway's HUNT Biobank
Jun 17, 2025 09:00AM
Jun 3, 2025 09:00AM
May 29, 2025 09:00AM
May 29, 2025 09:00AM
May 15, 2025 04:56AM
May 8, 2025 07:49AM
May 6, 2025 04:30PM BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates
Apr 24, 2025 08:28AM

325,893 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All